Severe Acute Respiratory Syndrome Coronavirus Infection Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major severe acute respiratory syndrome coronavirus infection markets reached a value of US$ 21.4 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 68.5 Billion by 2034, exhibiting a growth rate (CAGR) of 11.14% during 2024-2034.
The severe acute respiratory syndrome coronavirus infection market has been comprehensively analyzed in IMARC's new report titled "Severe Acute Respiratory Syndrome Coronavirus Infection Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Severe acute respiratory syndrome coronavirus infection, commonly known as SARS-CoV, is a viral pulmonary illness caused by the SARS coronavirus. The primary transmission mode of this ailment is through respiratory droplets when an infected individual sneezes or coughs. It can also spread by contacting surfaces contaminated with the virus and then touching the face. The common symptoms of the disorder include high fever, cough, shortness of breath, difficulty breathing, chills, body aches, headaches, diarrhea, nausea, vomiting, etc. In severe cases, individuals suffering from this disease may also experience pneumonia, respiratory distress, hypoxemia, or multiple organ failure. The diagnosis of SARS-CoV infection typically requires a combination of clinical presentation, medical history review, and a physical examination. Polymerase chain reaction testing is also used to detect the genetic material (RNA) of the virus in respiratory samples, such as nasal swabs, throat swabs, or sputum. The healthcare provider may further conduct chest X-rays and computed tomography scans to assess lung involvement and identify any characteristic patterns associated with the disease, like ground-glass opacities or consolidation.
The increasing prevalence of viral shedding through respiratory droplets when an infected individual sneezes, coughs, talks, or breathes heavily in close proximity to others is primarily driving the severe acute respiratory syndrome coronavirus infection market. In addition to this, the expanding geriatric population, who have weakened immunity, along with pre-existing health conditions like cardiovascular disease and diabetes, is also creating a positive outlook for the market. Moreover, the widespread adoption of immunomodulatory therapies, including intravenous immunoglobulin (IVIG) and monoclonal antibodies, to modulate the production and activity of pro-inflammatory cytokines is further bolstering the market growth. Apart from this, the inflating application of respiratory physiotherapy, since it involves techniques that help in clearing secretions from the lungs, improving pulmonary function, and promoting better breathing in patients is acting as another significant growth-inducing factor. Additionally, the emerging popularity of extracorporeal membrane oxygenation procedures, which provide circulatory support by ensuring adequate blood flow to vital organs, is expected to drive the severe acute respiratory syndrome coronavirus infection market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the severe acute respiratory syndrome coronavirus infection market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for severe acute respiratory syndrome coronavirus infection and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the severe acute respiratory syndrome coronavirus infection market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the severe acute respiratory syndrome coronavirus infection market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the severe acute respiratory syndrome coronavirus infection market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current severe acute respiratory syndrome coronavirus infection marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the severe acute respiratory syndrome coronavirus infection market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the severe acute respiratory syndrome coronavirus infection market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the severe acute respiratory syndrome coronavirus infection market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of severe acute respiratory syndrome coronavirus infection across the seven major markets?
What is the number of prevalent cases (2018-2034) of severe acute respiratory syndrome coronavirus infection by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of severe acute respiratory syndrome coronavirus infection by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with severe acute respiratory syndrome coronavirus infection across the seven major markets?
What is the size of the severe acute respiratory syndrome coronavirus infection patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of severe acute respiratory syndrome coronavirus infection?
What will be the growth rate of patients across the seven major markets?
Severe Acute Respiratory Syndrome Coronavirus Infection: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for severe acute respiratory syndrome coronavirus infection drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the severe acute respiratory syndrome coronavirus infection market?
What are the key regulatory events related to the severe acute respiratory syndrome coronavirus infection market?
What is the structure of clinical trial landscape by status related to the severe acute respiratory syndrome coronavirus infection market?
What is the structure of clinical trial landscape by phase related to the severe acute respiratory syndrome coronavirus infection market?
What is the structure of clinical trial landscape by route of administration related to the severe acute respiratory syndrome coronavirus infection market?
The severe acute respiratory syndrome coronavirus infection market has been comprehensively analyzed in IMARC's new report titled "Severe Acute Respiratory Syndrome Coronavirus Infection Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Severe acute respiratory syndrome coronavirus infection, commonly known as SARS-CoV, is a viral pulmonary illness caused by the SARS coronavirus. The primary transmission mode of this ailment is through respiratory droplets when an infected individual sneezes or coughs. It can also spread by contacting surfaces contaminated with the virus and then touching the face. The common symptoms of the disorder include high fever, cough, shortness of breath, difficulty breathing, chills, body aches, headaches, diarrhea, nausea, vomiting, etc. In severe cases, individuals suffering from this disease may also experience pneumonia, respiratory distress, hypoxemia, or multiple organ failure. The diagnosis of SARS-CoV infection typically requires a combination of clinical presentation, medical history review, and a physical examination. Polymerase chain reaction testing is also used to detect the genetic material (RNA) of the virus in respiratory samples, such as nasal swabs, throat swabs, or sputum. The healthcare provider may further conduct chest X-rays and computed tomography scans to assess lung involvement and identify any characteristic patterns associated with the disease, like ground-glass opacities or consolidation.
The increasing prevalence of viral shedding through respiratory droplets when an infected individual sneezes, coughs, talks, or breathes heavily in close proximity to others is primarily driving the severe acute respiratory syndrome coronavirus infection market. In addition to this, the expanding geriatric population, who have weakened immunity, along with pre-existing health conditions like cardiovascular disease and diabetes, is also creating a positive outlook for the market. Moreover, the widespread adoption of immunomodulatory therapies, including intravenous immunoglobulin (IVIG) and monoclonal antibodies, to modulate the production and activity of pro-inflammatory cytokines is further bolstering the market growth. Apart from this, the inflating application of respiratory physiotherapy, since it involves techniques that help in clearing secretions from the lungs, improving pulmonary function, and promoting better breathing in patients is acting as another significant growth-inducing factor. Additionally, the emerging popularity of extracorporeal membrane oxygenation procedures, which provide circulatory support by ensuring adequate blood flow to vital organs, is expected to drive the severe acute respiratory syndrome coronavirus infection market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the severe acute respiratory syndrome coronavirus infection market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for severe acute respiratory syndrome coronavirus infection and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the severe acute respiratory syndrome coronavirus infection market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the severe acute respiratory syndrome coronavirus infection market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the severe acute respiratory syndrome coronavirus infection market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current severe acute respiratory syndrome coronavirus infection marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the severe acute respiratory syndrome coronavirus infection market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the severe acute respiratory syndrome coronavirus infection market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the severe acute respiratory syndrome coronavirus infection market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of severe acute respiratory syndrome coronavirus infection across the seven major markets?
What is the number of prevalent cases (2018-2034) of severe acute respiratory syndrome coronavirus infection by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of severe acute respiratory syndrome coronavirus infection by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with severe acute respiratory syndrome coronavirus infection across the seven major markets?
What is the size of the severe acute respiratory syndrome coronavirus infection patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of severe acute respiratory syndrome coronavirus infection?
What will be the growth rate of patients across the seven major markets?
Severe Acute Respiratory Syndrome Coronavirus Infection: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for severe acute respiratory syndrome coronavirus infection drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the severe acute respiratory syndrome coronavirus infection market?
What are the key regulatory events related to the severe acute respiratory syndrome coronavirus infection market?
What is the structure of clinical trial landscape by status related to the severe acute respiratory syndrome coronavirus infection market?
What is the structure of clinical trial landscape by phase related to the severe acute respiratory syndrome coronavirus infection market?
What is the structure of clinical trial landscape by route of administration related to the severe acute respiratory syndrome coronavirus infection market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS INFECTION - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS INFECTION - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS INFECTION - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS INFECTION - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS INFECTION - UNMET NEEDS
10 SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS INFECTION - KEY ENDPOINTS OF TREATMENT
11 SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS INFECTION - MARKETED PRODUCTS
11.1 List of Severe Acute Respiratory Syndrome Coronavirus Infection Marketed Drugs Across the Top 7 Markets
11.1.1 Spikevax (Elasomeran) - Moderna Therapeutics
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Comirnaty (Tozinameran) - BioNTech/Pfizer
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Paxlovid (Nirmatrelvir + ritonavir) - Pfizer
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS INFECTION - PIPELINE DRUGS
12.1 List of Severe Acute Respiratory Syndrome Coronavirus Infection Pipeline Drugs Across the Top 7 Markets
12.1.1 TAK-019 - Takeda
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 MBSCOV - Oneness Biotech
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 SNG001 - Synairgen
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 NA 831 - NeuroActiva
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS INFECTION - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS INFECTION – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS INFECTION - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Severe Acute Respiratory Syndrome Coronavirus Infection - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Severe Acute Respiratory Syndrome Coronavirus Infection - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Severe Acute Respiratory Syndrome Coronavirus Infection - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Severe Acute Respiratory Syndrome Coronavirus Infection - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Severe Acute Respiratory Syndrome Coronavirus Infection - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Severe Acute Respiratory Syndrome Coronavirus Infection - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Severe Acute Respiratory Syndrome Coronavirus Infection - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Severe Acute Respiratory Syndrome Coronavirus Infection - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Severe Acute Respiratory Syndrome Coronavirus Infection - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Severe Acute Respiratory Syndrome Coronavirus Infection - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Severe Acute Respiratory Syndrome Coronavirus Infection - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Severe Acute Respiratory Syndrome Coronavirus Infection - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Severe Acute Respiratory Syndrome Coronavirus Infection - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Severe Acute Respiratory Syndrome Coronavirus Infection - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Severe Acute Respiratory Syndrome Coronavirus Infection - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Severe Acute Respiratory Syndrome Coronavirus Infection - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Severe Acute Respiratory Syndrome Coronavirus Infection - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Severe Acute Respiratory Syndrome Coronavirus Infection - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Severe Acute Respiratory Syndrome Coronavirus Infection - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Severe Acute Respiratory Syndrome Coronavirus Infection - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Severe Acute Respiratory Syndrome Coronavirus Infection - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Severe Acute Respiratory Syndrome Coronavirus Infection - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Severe Acute Respiratory Syndrome Coronavirus Infection - Access and Reimbursement Overview
16 SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS INFECTION - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS INFECTION MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS INFECTION MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS INFECTION - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS INFECTION - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS INFECTION - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS INFECTION - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS INFECTION - UNMET NEEDS
10 SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS INFECTION - KEY ENDPOINTS OF TREATMENT
11 SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS INFECTION - MARKETED PRODUCTS
11.1 List of Severe Acute Respiratory Syndrome Coronavirus Infection Marketed Drugs Across the Top 7 Markets
11.1.1 Spikevax (Elasomeran) - Moderna Therapeutics
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Comirnaty (Tozinameran) - BioNTech/Pfizer
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Paxlovid (Nirmatrelvir + ritonavir) - Pfizer
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS INFECTION - PIPELINE DRUGS
12.1 List of Severe Acute Respiratory Syndrome Coronavirus Infection Pipeline Drugs Across the Top 7 Markets
12.1.1 TAK-019 - Takeda
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 MBSCOV - Oneness Biotech
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 SNG001 - Synairgen
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 NA 831 - NeuroActiva
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS INFECTION - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS INFECTION – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS INFECTION - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Severe Acute Respiratory Syndrome Coronavirus Infection - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Severe Acute Respiratory Syndrome Coronavirus Infection - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Severe Acute Respiratory Syndrome Coronavirus Infection - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Severe Acute Respiratory Syndrome Coronavirus Infection - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Severe Acute Respiratory Syndrome Coronavirus Infection - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Severe Acute Respiratory Syndrome Coronavirus Infection - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Severe Acute Respiratory Syndrome Coronavirus Infection - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Severe Acute Respiratory Syndrome Coronavirus Infection - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Severe Acute Respiratory Syndrome Coronavirus Infection - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Severe Acute Respiratory Syndrome Coronavirus Infection - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Severe Acute Respiratory Syndrome Coronavirus Infection - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Severe Acute Respiratory Syndrome Coronavirus Infection - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Severe Acute Respiratory Syndrome Coronavirus Infection - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Severe Acute Respiratory Syndrome Coronavirus Infection - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Severe Acute Respiratory Syndrome Coronavirus Infection - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Severe Acute Respiratory Syndrome Coronavirus Infection - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Severe Acute Respiratory Syndrome Coronavirus Infection - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Severe Acute Respiratory Syndrome Coronavirus Infection - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Severe Acute Respiratory Syndrome Coronavirus Infection - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Severe Acute Respiratory Syndrome Coronavirus Infection - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Severe Acute Respiratory Syndrome Coronavirus Infection - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Severe Acute Respiratory Syndrome Coronavirus Infection - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Severe Acute Respiratory Syndrome Coronavirus Infection - Access and Reimbursement Overview
16 SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS INFECTION - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS INFECTION MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS INFECTION MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
